Laidlaw Capital Markets served as Financial Advisor on the $115,000,000 Follow-On Offering for EyePoint Pharmaceuticals

The Team at Laidlaw Capital Markets is pleased to have acted as Financial Advisor on the $115,000,000 Follow-On Offering, alongside Guggenheim and Cowen. This is the third transaction Laidlaw has been a part of with the company and we look forward to their continued success.

Laidlaw Capital Markets served as Financial Advisor on the $115,000,000 Follow-On Offering for EyePoint Pharmaceuticals2021-02-10T14:34:06+00:00

Laidlaw Wealth Management Acquires Naples Wealth Planning

Laidlaw Wealth Management is pleased to announce its acquisition and partnership with Naples Wealth Planning.

NEW YORK, NY, USA, October 19, 2020 /EINPresswire.com/ — Laidlaw Wealth Management is pleased to announce its acquisition and partnership with Naples Wealth Planning a well-recognized and respected RIA based in Naples, Florida.

The agreement will add four new offices in Naples, Tampa, Stuart, and Miami to Laidlaw’s existing Florida location in Boca Raton. In addition, this launches a new platform at Laidlaw to service and expand the 1099 model for advisors. This is an area Richard Calhoun, CEO of Laidlaw Wealth Management, knows well as he was instrumental in the growth of the Wells Fargo Advisors Financial Network from 245 offices to 642 offices, as Managing Director of Growth and Innovation.

Laidlaw Wealth Management Acquires Naples Wealth Planning2020-10-20T21:17:59+00:00

Laidlaw Venture Partners Continues Strategic Growth with Addition of Mr. Anthony Zook to its Investment and Operations Committee

Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the addition of Mr. Anthony (‘Tony’) Zook to its newly formed Investment and Operations Committee. As a global industry leader, Zook brings years of strategic experience to Laidlaw Venture Partners and is expected to be instrumental in the further development and evolution of the LVP portfolio of companies.

Laidlaw Venture Partners Continues Strategic Growth with Addition of Mr. Anthony Zook to its Investment and Operations Committee2020-10-18T19:28:09+00:00

Laidlaw Venture Partners Continues Strategic Growth with Addition of Jeff Conroy and George Serafin to its Board of Advisors

Laidlaw Venture Partners, the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the addition of Jeff Conroy and George Serafin to its Board of Advisors. As industry leaders in Business Development and Regulatory/Compliance, both Conroy and Serafin bring years of strategic experience to Laidlaw Venture Partners and will be instrumental in the development and evolution of our innovative companies.

Laidlaw Venture Partners Continues Strategic Growth with Addition of Jeff Conroy and George Serafin to its Board of Advisors2020-06-25T19:00:05+00:00

Laidlaw Venture Partners Adds Industry Leading CEOs Jeffrey O’Donnell and Dr. Ann Marie Sastry to its Board of Advisors

Laidlaw Venture Partners, the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the addition of Jeff Conroy and George Serafin to its Board of Advisors. As industry leaders in Business Development and Regulatory/Compliance, both Conroy and Serafin bring years of strategic experience to Laidlaw Venture Partners and will be instrumental in the development and evolution of our innovative companies.

Laidlaw Venture Partners Adds Industry Leading CEOs Jeffrey O’Donnell and Dr. Ann Marie Sastry to its Board of Advisors2020-10-18T19:22:42+00:00

Laidlaw served as Introducing Broker on the $10.8mm financing for Biosig Technologies (BSGM), through its subsidiary ViralClear.

Laidlaw Venture Partners client Biosig Technologies (BSGM) through its newly formed subsidiary ViralClear, closes $10,800,000 financing. Laidlaw is proud to have acted as am Introducing Broker on this financing.

Laidlaw served as Introducing Broker on the $10.8mm financing for Biosig Technologies (BSGM), through its subsidiary ViralClear.2020-06-01T15:29:30+00:00

Laidlaw served as Financial Advisor on the $70mm Follow-On Offering for Arcturus Therapeutics (ARCT).

Laidlaw Capital Markets is pleased to announce today’s pricing of a $70,000,000 Follow-On Offering for Arcturus Therapeutics (ARCT) around its Covid-19 vaccine and platform for other diseases. Laidlaw proudly served as Financial Advisor alongside Guggenheim, who was Sole-Book Runner on the transaction.

Laidlaw served as Financial Advisor on the $70mm Follow-On Offering for Arcturus Therapeutics (ARCT).2020-06-01T15:21:16+00:00
Go to Top